_Neven GYN ONCOL MBC UZKULeuven妇科肿瘤学和MBC P内文乌斯鲁汶大学课件.pptVIP

下载本文档

1
0
约1.82万字
约 46页
2018-06-19 发布于贵州
举报
版权申诉

_Neven GYN ONCOL MBC UZKULeuven妇科肿瘤学和MBC P内文乌斯鲁汶大学课件.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

_Neven GYN ONCOL MBC UZKULeuven妇科肿瘤学和MBC P内文乌斯鲁汶大学课件

OngoingClinical Research TrialsMultidisciplinary Breast Centre Ten most frequently occuring tumours in Flanders, 2000 - 2001 Age-specific incidence of breast cancer in women, Flanders, 1997-2001 May be the incidence will come down? I. OngoingClinical Trials I. Clinical Trials Recently Closed Clinical Trials Recruiting Clinical Trials Future Clinical Trials Recruiting Clinical Trials OngoingClinical Trials IBIS-2Recruiting Centres St.Luc Brussel St.Pierre Brussel VUB Brussel Virga Jesse Hasselt St.Elisabeth Namen St.Augustinus Wilrijk Erasmus Brussel Bordet Brussel Heilig Hart Leuven OLVrouwZH Aalst ZOL Genk Clinique St.Pierre Ottignies CHR Citadelle Luik Brugmann Brussel Centre Hospitalier de l’Ardenne Recruiting Clinical Trials First Line: TTP Benefit of Fulvestrant over Tamoifenin ER+ PgR+ Patients* Fulvestrant 250 mg/month Provides Long-term Downregulation of ER Levels Fulvestrant induces dose-related ER downregulation(PgR and Ki67)* Finder-II Current Future Clinical Trials?Targeted Therapies Two Targets, One DrugLapatinib Profile Lapatinib is a novel oral dual-tyrosine kinase inhibitor with specificity for the ErbB-1 andErbB-2 receptors Belongs to the 4-anilinoquinazoline class of tyrosine kinase inhibitors Binds reversibly to the cytoplasmic ATP-binding site of the kinase, thereby preventing receptor phosphorylation and activation ALTTO STUDY DESIGN Four-arm, randomised, open-label and multicentre study in women with primary breast cancer that over expresses or amplifies HER2. Sample Size 8000 patients Primary Endpoint: DFS Secondary Endpoints OS TTR (time to recurrence) TTDR (Time to distant recurrence) Safety and tolerability Proposed start 2Q07 Study duration: 5 years (4 years for enrolment and 1 year as follow-up) 2 Interim analyses (at 600 and 1000 DFS events, approximately) ALTTO STUDY DESIGN 4 Arms: Trastuzumab for 52 wks Lapatinib for 52 wks Trastuzumab + Lapatinib for 52 wks Trastuzumab for 12 wks, 6 wk washout, Lapatinib for 34 wks